Loading…
Our read is that multi-cancer early detection via liquid biopsy is well supported, particularly as a confirmatory test.
Our read is that liquid biopsy tests for multi-cancer early detection are well supported, offering a manual trade-off between sensitivity and specificity akin to PSA testing. These tests hold potential for detecting micro-metastatic disease by measuring contributions from multiple deposits.
However, their utility is dependent on stratifying populations by genetic risk, as their usefulness varies within different risk cohorts.
Peter Attia raises a significant concern (1x) regarding the subsequent course of action if a liquid biopsy indicates pancreatic cancer.
The verdict could change with further expert consensus on the appropriate follow-up actions for positive liquid biopsy results, especially for hard-to-treat cancers, or new data on their efficacy as primary screening tools across diverse populations.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Mechanistic and trial evidence converge on a real, replicable effect.
Benefits hold across the populations where it's been tested.
The intervention improves the primary outcome at standard doses in healthy adults.
Mechanistic and trial evidence converge on a real, replicable effect.
The intervention improves the primary outcome at standard doses in healthy adults.
Animal-model results don't translate to the human protocol being recommended.
Confounding and publication bias inflate the apparent benefit.
Most of the support comes from short or small studies.
Confounding and publication bias inflate the apparent benefit.
The headline effect shrinks once you account for trial quality.